Key result
Co-administration of RNAx with a saRNA-LNP vaccine decreased serum biomarkers of reactogenicity while maintaining or enhancing antibody and cellular responses in preclinical models.
Why the study?
RNA vaccine platforms trigger undesirable side effects at protective doses, underscoring the need for improved tolerability.
Answers are grounded in this paper and cite their sources.
Co-administration of a leader-protein-encoding mRNA (RNAx) with saRNA vaccines reduces reactogenicity while preserving or enhancing immunogenicity in preclinical models.
Self-amplifying RNA (saRNA)-based vaccines have emerged as a potent and durable RNA vaccine platform. However, RNA vaccine platforms trigger undesirable side effects at protective doses, underscoring the need for improved tolerability. To address this, we leveraged the Cardiovirus leader protein, which is well-characterized to dampen host innate signaling by modulating nucleocytoplasmic transport (NCT). Co-administration of a leader-protein-encoding mRNA (which we have named “RNAx”) delivered alongside vaccine cargo saRNA reduced interferon production while enhancing Influenza hemagglutinin (HA) expression in human primary cells and murine models. RNAx potently decreased serum biomarkers of reactogenicity after immunizations with an HA-expressing saRNA-LNP vaccine while maintaining the magnitude of the antibody and cellular response. RNAx also consistently enhanced binding antibody titers after a single injection and in some conditions enhanced binding antibody and neutralization titers post-boost. These findings support RNAx as a promising platform approach for improving tolerability of saRNA-LNP vaccines while preserving or enhancing immunogenicity.
No takes yet. Share an insight, caveat, or question.
Wojcechowskyj et al. (2024) studied Vaccine reactogenicity. RNAx (leader-protein-encoding mRNA) was evaluated on Reactogenicity biomarkers and immunogenicity. Co-administration of RNAx with a saRNA-LNP vaccine decreased serum biomarkers of reactogenicity while maintaining or enhancing antibody and cellular responses in preclinical models.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: